This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock ORPN vs. BPTH, ONCT, VAXX, ASLN, CWBR, EVFM, PBLA, TRVN, HEPA, and PTPIShould you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Bio-Path (BPTH), Oncternal Therapeutics (ONCT), Vaxxinity (VAXX), ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Evofem Biosciences (EVFM), Panbela Therapeutics (PBLA), Trevena (TRVN), Hepion Pharmaceuticals (HEPA), and Petros Pharmaceuticals (PTPI). These companies are all part of the "medical" sector. Bioblast Pharma vs. Its Competitors Bio-Path Oncternal Therapeutics Vaxxinity ASLAN Pharmaceuticals CohBar Evofem Biosciences Panbela Therapeutics Trevena Hepion Pharmaceuticals Petros Pharmaceuticals Bio-Path (NASDAQ:BPTH) and Bioblast Pharma (NASDAQ:ORPN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations. Does the media favor BPTH or ORPN? In the previous week, Bio-Path had 1 more articles in the media than Bioblast Pharma. MarketBeat recorded 1 mentions for Bio-Path and 0 mentions for Bioblast Pharma. Bio-Path's average media sentiment score of 0.00 equaled Bioblast Pharma'saverage media sentiment score. Company Overall Sentiment Bio-Path Neutral Bioblast Pharma Neutral Do analysts rate BPTH or ORPN? Bio-Path currently has a consensus price target of $20.00, indicating a potential upside of 12,245.68%. Given Bio-Path's stronger consensus rating and higher possible upside, equities analysts clearly believe Bio-Path is more favorable than Bioblast Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bioblast Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals have more ownership in BPTH or ORPN? 5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 4.5% of Bioblast Pharma shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, BPTH or ORPN? Bio-Path has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Is BPTH or ORPN more profitable? Bioblast Pharma's return on equity of 0.00% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% Bioblast Pharma N/A N/A N/A Which has preferable valuation and earnings, BPTH or ORPN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/ABioblast PharmaN/AN/A-$5.94MN/AN/A SummaryBio-Path beats Bioblast Pharma on 6 of the 10 factors compared between the two stocks. Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORPN vs. The Competition Export to ExcelMetricBioblast PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$508K$772.39M$5.42B$8.78BDividend YieldN/A4.84%5.37%4.22%P/E RatioN/A1.1125.6619.58Price / SalesN/A223.99387.24108.03Price / CashN/A23.4436.0256.31Price / Book0.166.127.855.50Net Income-$5.94M-$26.79M$3.15B$248.79M Bioblast Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORPNBioblast PharmaN/A$1.21-4.0%N/A-7.4%$508KN/A0.00N/AHigh Trading VolumeBPTHBio-Path1.844 of 5 stars$0.19-5.3%$20.00+10,454.1%-91.7%$1.57MN/A0.0010ONCTOncternal TherapeuticsN/A$0.53flat$10.00+1,799.0%N/A$1.56M$790K-0.0530Positive NewsVAXXVaxxinityN/A$0.01+9,900.0%N/A-86.8%$1.27MN/A-0.0290ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330CWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010EVFMEvofem Biosciences0.5035 of 5 stars$0.01+1.0%N/A-5.9%$1.15M$11.39M-0.02120News CoverageNegative NewsPBLAPanbela Therapeutics0.0494 of 5 stars$0.23-3.3%N/A-44.9%$1.13MN/A0.006High Trading VolumeTRVNTrevena1.7687 of 5 stars$1.14flat$5.00+338.6%-80.8%$1.09M$443K-0.0240HEPAHepion Pharmaceuticals0.6339 of 5 stars$0.09+8.9%N/A-99.9%$962KN/A-0.0220Gap UpPTPIPetros Pharmaceuticals0.2249 of 5 stars$0.03-10.0%N/A-99.7%$841K$5.11M-0.0120News CoverageNegative News Related Companies and Tools Related Companies Bio-Path Competitors Oncternal Therapeutics Competitors Vaxxinity Competitors ASLAN Pharmaceuticals Competitors CohBar Competitors Evofem Biosciences Competitors Panbela Therapeutics Competitors Trevena Competitors Hepion Pharmaceuticals Competitors Petros Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORPN) was last updated on 6/27/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
